## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.3% below STRENGTH zone (4.0-10.0%); PEG 2.19 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($117.64)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Total equity of Zoetis, Inc. Class A – SIX:ZTS**
- Source: TradingView | 20251201T172158 | Neutral | Relevance: 99%
- This page provides financial data for Zoetis, Inc. Class A (SIX:ZTS) specifically focusing on total equity. It serves as a financial overview for investors interested in the company's balance sheet information. The content lists the company's name and stock symbol, alongside a table for total equity value, change, and change percentage over various periods.

**2. How Zoetis Inc. Class A (ZTS) Affects Rotational Strategy Timing**
- Source: Stock Traders Daily | 20251201T233800 | Bullish | Relevance: 98%
-  This article analyzes Zoetis Inc. Class A (ZTS) focusing on its impact on rotational strategy timing, identifying strong near and mid-term sentiment but a weak long-term outlook. It details specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, with corresponding entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal analysis, showing support and resistance levels for ZTS.

**3. What Zoetis (ZTS)'s European Approval for Lenivia Means for Shareholders**
- Source: Sahm | 20251201T131700 | Bullish | Relevance: 97%
-  Zoetis received European Commission marketing authorization for Lenivia®, a long-acting monoclonal antibody therapy for canine osteoarthritis pain, providing three months of relief with a single injection. This approval reinforces Zoetis's innovation-driven strategy in animal health, particularly in companion animal pain management. While it strengthens their pipeline, the company still needs to address ongoing challenges such as slower-than-expected adoption of their other pain therapies like Librela due to safety concerns.

**4. Moderna (MRNA) Leads Healthcare Gains with 16.19% Surge**
- Source: GuruFocus | 20251130T085500 | Somewhat-Bullish | Relevance: 62%
- Moderna (MRNA) surged 16.19% last week, leading the S&P 500 healthcare sector amidst a broader market rally. Despite strong liquidity and low debt, the company faces significant challenges with negative revenue growth and profitability, indicated by a low Piotroski F-Score and mid-range Altman Z-Score. Its valuation shows mixed signals with a neutral RSI-14 and a GF Score of 55, classifying it as a distressed stock.

### Analyst Activity

**Target Signal:** BEARISH (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $136 | $0 | 0% |
| 2025-12-03 | BTIG | $160 | $160 | 0% |
| 2025-11-21 | Keybanc | $0 | $0 | 0% |
| 2025-11-18 | Stifel | $130 | $140 | -7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |
| 2025-12-03 | BTIG | reit | Buy |
| 2025-11-21 | Keybanc | init | Sector Weight |
| 2025-11-18 | Stifel | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 18.0% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.19 elevated, pricing in significant growth expectations. Forward P/E 18.3x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $52.3B |
| Beta | 0.97 |
| 52W Range | $115.25 - $181.85 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.19 |
| Forward P/E | 18.3 |
| Current P/E | 19.6 |
| YoY Growth | 7.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.5% to 0.3% (-2.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.7pp (needs >4.0% for momentum thesis). MRS_5 (-2.7%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.82x), long-term trend not supportive. MACD histogram positive (1.55), confirming momentum. RSI neutral at 43.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.33% (CS: 63) | Neutral |
| RSI_14 | 42.7 | Neutral |
| MACD Histogram | 1.55 | Bullish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 0.919x | Below |
| vs SMA200 | 0.820x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $124.44
- **Stop Loss:** $117.64 (5.5% risk)
- **Target:** $131.24 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 147
- **Position Value:** $18,292.68
- **Portfolio %:** 18.29%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*